Cara Therapeutics Inc (NAS:CARA)
$ 0.378 -0.0719 (-15.98%) Market Cap: 20.73 Mil Enterprise Value: -13.94 Mil PE Ratio: 0 PB Ratio: 37.80 GF Score: 35/100

Cara Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 01:00AM GMT
Release Date Price: $16.89 (+0.54%)
Daniel G. Wolle
JP Morgan Chase & Co, Research Division - Analyst

Good afternoon. My name is Daniel Wolle. I'm one of the associates on the biotech team. We're continuing the 2020 Healthcare -- the JPM Healthcare with Cara Therapeutics. After their presentation, the breakout sessions will be held in the Olympic Room. Before that though, I present Derek Chalmers, CEO of Cara Therapeutics.

Derek T. Chalmers
Cara Therapeutics, Inc. - Co-Founder, President, CEO & Director

Great. Thank you, Daniel. Good afternoon, everybody. Thanks for staying late this afternoon. So what I'm going to do this morning -- I'm sorry, this afternoon, is run through our basic therapeutic focus very briefly, then update you on our various clinical programs and our advancement there through last year and what we expect this year and then finish with the major milestones for the year. Of course, there will be some forward-looking statements.

So Cara today is a company focused on developing a novel therapeutic approach for the treatment of chronic systemic pruritus. And I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot